Zeven (dalbavancin) / RaQualia, AbbVie - LARVOL DELTA

A Peptidoglycan-Mimetic Nanopore Receptor Resolves Glycopeptide Antibiotic Recognition and Resistance at the Single-Molecule Level. (PubMed, ACS Sens) - "In addition, the PGP-αHL platform enables reliable discrimination of structurally similar GPAs, including vancomycin, teicoplanin, and dalbavancin, achieving approximately 99% overall classification accuracy when combined with machine learning. The applicability of this approach is further demonstrated by the detection of GPA residues in spiked milk samples. This work establishes a target-mimetic nanopore receptor strategy that integrates single-molecule analysis of antibiotic-target recognition, resistance-associated binding alterations, and discrimination of structurally similar antibiotics within a unified sensing platform."

Journal • Infectious Disease

Economic Outcomes of Dalbavancin versus Standard Therapy in Staphylococcus aureus Bacteremia in the DOTS Randomized Clinical Trial. (PubMed, Clin Infect Dis) - "On average, savings from reduced inpatient care and less OPAT fully offset the higher cost of dalbavancin in patients with SAB. Savings were greater in patients with IDU."

Clinical • HEOR • Journal

Staphylococcus pettenkoferi: an underrecognized species with clinically relevant antimicrobial resistance. A comprehensive genomic European study. (PubMed, Emerg Microbes Infect) - "Susceptibility rates were below 70% for cefoxitin, erythromycin, and levofloxacin, whereas high susceptibility (>90%) was observed for vancomycin, teicoplanin, dalbavancin, aminoglycosides, oxazolidinones, trimethoprim-sulfamethoxazole, fusidic acid, and tetracycline. Nearly all isolates (92.1%) were fosfomycin-resistant...This study provides a comprehensive genomic and phenotypic assessment of antimicrobial resistance in S. pettenkoferi, revealing widespread multidrug-resistant lineages, including ceftobiprole- and daptomycin-resistant isolates across distinct clades. These findings underscore the need for continued surveillance and improved diagnostics for this increasingly encountered CoNS species."

Journal • Infectious Disease • Inflammation

A Real-World Evaluation of Dalbavancin Utilization, Institutional Guideline Concordance, and Outpatient Care Gaps (IDWeek 2026) - No abstract available

Clinical • Discordant • HEOR • Real-world • Real-world evidence • Infectious Disease

Intravenous Dalbavancin Versus Standard of Care Antibiotics for Treatment of Invasive Gram-Positive Infections (IDWeek 2026) - No abstract available

Gram positive • Infectious Disease

Real-world Use and Impact of Dalbavancin for Skin and Soft Tissue Infections in the Emergency Department (IDWeek 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Infectious Disease

Infection-related Outcomes of Dalbavancin for Prosthetic Joint and Spinal Hardware Infections (IDWeek 2026) - No abstract available

Infectious Disease

Exploratory Evaluation of Predictors of Clinical Outcomes with Dalbavancin Sequential Therapy for Gram-Positive Bloodstream Infections: A Multicenter Cohort Study (IDWeek 2026) - No abstract available

Clinical • Clinical data • Gram positive • Infectious Disease

Real World Dalbavancin Use in the Emergency Department at a Newly Integrated Academic Hospital (IDWeek 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Infectious Disease

Utilization of Dalbavancin and its Effect on Hospital Days Saved for Gram Positive Infections (IDWeek 2026) - No abstract available

Clinical • Gram positive • Infectious Disease

Dalbavancin in High-Risk Patients: Real-World Safety with Zero 30-Day Mortality (IDWeek 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Infectious Disease

Understanding Dalbavancin Use Among Infectious Diseases Clinicians: A Single-Center, Mixed-Methods Survey (IDWeek 2026) - No abstract available

Clinical • Infectious Disease

A Rapid Infectious Diseases - Emergency Department Dalbavancin Program for High Risk Patients at an Urban Safety Net Medical Center: Prospective Cohort Study (IDWeek 2026) - No abstract available

Clinical • Infectious Disease

When IV Is Not an Option: Ethics, Economics and Real-Life Questions in Treating Infections in People Who Use Drugs (IDWeek 2026) - "Organized by Co-Organizing Groups: n/a Learning Objectives: At the conclusion of this session, participants will be able to:Describe evidence for risks of using IV antibiotics in persons with substance use disorderEvaluate the evidence for using long-acting dalbavancin for complicated staphylococcus aureus infections in people with substance use disorderAssess evidence for use of oral antibiotic therapy for complicated staphylococcus aureus infections in people with substance use disorder"

Clinical • Infectious Disease

Single-dose Antibiotics for Treatment of Skin and Soft Tissue Infections. (PubMed, Infect Dis Clin North Am) - "There are 2 long-acting lipoglycopeptides available in the United States, dalbavancin and oritavancin, which have broad gram-positive activity and significantly long-half lives, allowing for single-dose therapy. These drugs can prevent patients from requiring hospitalization for intravenous antibiotics or expedite discharge for those already admitted. They also have a role in patients with barriers to succeeding with oral antibiotics due to adherence challenges or contraindications."

Journal • Review • Infectious Disease

Strategy for enhanced production of A40926B0 in Nonomuraea gerenzanensis using an efficient CRISPR/AsCas12f1 system. (PubMed, Synth Syst Biotechnol) - "The global emergence of vancomycin-resistant Gram-positive pathogens underscores the urgent need for efficient production of novel lipoglycopeptide antibiotics. Dalbavancin, a last-resort therapeutic agent, relies on its key biosynthetic precursor A40926B0, whose industrial manufacture is severely limited by the low yield of wild-type Nonomuraea gerenzanensis and inefficient genetic tools for this rare actinomycete...Finally, 50-L fed-batch fermentation with continuous maltodextrin feeding further increased the titer to 1817 mg/L, the highest reported titer to date. This work establishes a robust CRISPR editing tool for N. gerenzanensis and provides valuable engineering references for precursor-oriented strain improvement targeting lipoglycopeptide antibiotics, offering insights for the industrial scale production of A40926B0."

Journal • Infectious Disease

Antimicrobial Resistance in Major Gram-Positive Pathogens: Beyond the Vancomycin Border. (PubMed, Antibiotics (Basel)) - "The increasing prevalence of multidrug-resistant (MDR) Gram-positive infections has led to the widespread use of vancomycin and other next-line agents including linezolid, daptomycin, ceftaroline and dalbavancin. Additionally, resistance surveillance, antimicrobial stewardship and the development of novel antimicrobials are warranted to address the rising threat of resistant Gram-positive infections. This review aims to provide an overview of resistance mechanisms in major Gram-positive pathogens and discuss existing and emerging approaches to overcome resistance to agents beyond vancomycin, incorporating recent evidence on combination therapies and providing a practical treatment algorithm."

Journal • Review • Infectious Disease

Clinical outcomes of dalbavancin versus standard therapy for non-severe skin and soft-tissue infections as well as bone and joint infections: a retrospective observational study. (PubMed, JAC Antimicrob Resist) - "Dalbavancin treatment was associated with significantly fewer hospitalizations than standard therapy in non-severe cases of SSTI and BJI. The results should be interpreted cautiously due to selection bias and potential unmeasured confounders."

Clinical data • Journal • Observational data • Retrospective data • Infectious Disease

Production improvement of dalbavancin precursor A40926B0 in Nonomuraea gerenzanensis through strain reconstruction and fermentation optimization. (PubMed, Synth Syst Biotechnol) - "Following single-factor evaluations of shake-flask parameters, a Box-Behnken design (BBD)-based response surface methodology (RSM) was employed for systematic medium formulation, successfully elevating the titer to 1.41 g/L. Finally, this optimized process was successfully scaled to a 15 L bioreactor and the final A40926B0 titer reached 2.27 g/L, representing a 303.2% increase over the initial process, laying a foundation for the industrial-scale production of A40926B0."

Journal

Expanding the Role of Dalbavancin in Children: A Case Series and Systematic Review. (PubMed, Pediatr Infect Dis J) - "Dalbavancin was well tolerated and was associated with favorable outcomes in selected pediatric patients with severe Gram-positive infections, supporting its potential role in facilitating early discharge and outpatient management. Prospective multicenter studies are needed to better define its safety and effectiveness beyond acute bacterial skin and skin structure infections."

Journal • Cardiovascular • Infectious Disease • Inflammation • Pediatrics

Synergy between orally bioavailable antibiotics and dalbavancin against MRSA. (PubMed, J Antimicrob Chemother) - "Cefadroxil is a first-generation cephalosporin, like cephalexin, but with a longer half-life that allows for a typical 12-h dosing interval. In our study, we found that synergy between cefadroxil and dalbavancin was common regardless of susceptibility to cefadroxil or dalbavancin, suggesting that this might be a promising companion agent to add to dalbavancin in patients with deep-seated infections that may benefit from synergistic activity to enhance bactericidal effects. Trimethoprim/sulfamethoxazole and moxifloxacin may improve activity and are unlikely to be antagonistic. Clarithromycin and doxycycline seem least likely to offer a benefit."

Journal • Infectious Disease

Clinical efficacy and safety profile of long-acting lipoglycopeptides versus daily intravenous antibiotics for acute bacterial skin and skin structure infections (ABSSSI): a retrospective study in Greece. (PubMed, J Chemother) - "This was a retrospective, single-centre, observational study including 125 patients with skin and soft tissue infections who were either treated with LGPs such as dalbavancin or oritavancin (Group A, n = 62), or with standard daily IV therapy including vancomycin, linezolid, or daptomycin (Group B, n = 63). Furthermore, the incidence of adverse events was lower in the LGP group (Group A: 8.06% vs. Group B: 25.4%). Long-acting lipoglycopeptides demonstrated comparable clinical success rates to conventional daily intravenous antibiotics for the treatment of ABSSSI, with a 'favorable safety profile.' Moreover, the reduced cost and shorter hospitalization further support the use of LGPs as a safe and effective alternative for managing these infections."

Journal • Retrospective data • Infectious Disease

Projected health-service cost impact of dalbavancin consolidation therapy for Staphylococcus aureus bacteraemia in an Australian public health system. (PubMed, Intern Med J) - "Within an Australian public healthcare setting, dalbavancin consolidation therapy for selected patients with SAB was projected to reduce per-patient resource utilisation, particularly among those requiring prolonged HITH therapy. Reduced HITH bed utilisation and avoidance of central venous access were the principal contributors."

Journal

Operationalizing Single-Dose Long-Acting Lipoglycopeptides for Treatment of ABSSSI in a U.S. Community Hospital Emergency Department. (PubMed, Clin Drug Investig) - "An ED-based LaLGP protocol for ABSSSI management was feasible for selected clinically stable patients. Although some outcomes were numerically higher in the post-implementation group, the small sample size and low event rates limited definitive comparisons."

Journal • Infectious Disease

Saving Beds and Budgets: Real-World Efficacy, Safety, and Pharmacoeconomics of Long-Acting Lipoglycopeptides (LALs) in a Day Hospital Setting. (PubMed, Pathogens) - "In this uncontrolled, retrospective cohort, LAL-based day hospital management was feasible and associated with favorable observed clinical outcomes, an acceptable safety profile, and a potential for cost offset in selected patients with Gram-positive infections, including complex off-label indications. Because no matched inpatient or conventional OPAT comparator was included, these findings should be regarded as hypothesis-generating and cannot establish comparative efficacy, superiority, or actual cost savings."

HEOR • Journal • Real-world evidence • Cardiovascular • Immunology • Infectious Disease • Inflammation • Rheumatology